6Testing — from Sanger to next-generation

TA hundred-gene problem

The genetic heterogeneity of deafness (Module 5) is not just a conceptual challenge — it is a testing one. With over a hundred candidate genes and no way to guess which is at fault from the audiogram alone, a method that reads one gene per test is hopeless. The history of deafness genetics is, in large part, the history of the technology that overcame this.[2011]

CSanger — one gene at a time

Sanger sequencing, developed in 1977, was for decades the gold standard for reading DNA — accurate, but serial: one gene, even one exon, at a time. For a single-gene disease that is fine; for a hundred-gene one it is prohibitively slow and expensive. In practice, Sanger-era testing meant checking only GJB2 and giving up if it was normal.

CMicroarrays — fixed mutations

An intermediate step used microarrays that interrogate a pre-chosen set of known mutations (platforms such as the HHL-APEX array and OtoCHIP). These screen several genes at once, but only at positions known in advance — they miss novel variants and cover only a handful of genes. Useful, but far from comprehensive.

CMassively parallel sequencing

The breakthrough was massively parallel (next-generation) sequencing combined with targeted genomic enrichment — capturing just the deafness genes of interest, then sequencing them millions of reads at a time. A single such panel, OtoSCOPE being the best-known, screens all known deafness genes simultaneously, detecting both known and novel variants. This is what made comprehensive genetic diagnosis of deafness practical and affordable.[2010]

CExome & genome

Beyond targeted panels lie whole-exome (all coding sequence) and whole-genome sequencing. They read still more — a whole genome, which took the Human Genome Project over a decade, now takes days — but for deafness specifically, the targeted panel remains the efficient clinical choice: it covers the relevant genes at high depth without the cost and interpretive burden of the whole genome.

FTWhy this matters here

The technology is the enabler of everything else in this chapter. Only because a comprehensive panel can name the gene cheaply does genetic testing become a realistic part of the implant evaluation — turning the gene landscape into an actual prognosis for an actual patient. How that testing should be deployed in the work-up is the next module.